Roche Warns On Anti-Trust Zeal While Posting Painful Q1
But Says Biosimilar Erosion ‘Has Already Hit High Watermark’
Biosimilar erosion and slack drugs sales caused by the pandemic depressed Roche’s first quarter pharma revenue while its diagnostics unit saw sales soar on COVID testing.
You may also be interested in...
Roche’s Q1 update highlighted some key coming drug catalysts and early stage clinical efforts, including those for a potential COVID pill and for targeted cancer vaccines.
Investors during Roche’s first-quarter update 21 April will be looking for guidance on the strong growth of biosimilar competition to its cancer mainstays and how this may be offset by the group’s pipeline.
Antitrust regulators in the US, Europe and elsewhere say they will now collaborate on how to best assess pharmaceutical mergers, in a move that could restrict deals on grounds they excessively raise prices paid by consumers or dampen medical innovation.